
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals Inc. is poised for growth in the ACTH gel market, with projected revenue increases driven by rising prescription volumes and brand demand. The company's adjusted operating margin is anticipated to improve significantly from 25.4% in 2024 to 29.7% by 2028, alongside expected operating cash flow exceeding $630 million from 2025 to 2028. Furthermore, recent Q4 results demonstrated strong performance, allowing for raised revenue estimates for FY 2025, underscoring ANI's robust positioning in both the generic and specialty pharmaceutical markets.
Bears say
ANI Pharmaceuticals has experienced a notable decline in revenue within its Brands segment during the second and third quarters of 2024, primarily attributed to adverse market conditions impacting certain product molecules. Specifically, Cortrophin has faced consistent pricing headwinds, resulting in lower revenues in the first quarters of both 2023 and 2024, with a projected steep decline of over 30% anticipated in the first quarter of 2025 due to seasonality and Medicare-related issues affecting market access. Furthermore, despite a strong overall revenue performance in recent quarters, ongoing challenges related to market access and reliance on non-profit foundations for patient co-pays raise concerns about the sustainability and growth prospects of its product lines moving forward.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares